Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the easy-accordion-free domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u144920493/domains/currencyveda.com/public_html/wp-includes/functions.php on line 6114

Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /home/u144920493/domains/currencyveda.com/public_html/wp-includes/functions.php on line 6114
Torrent Pharmaceuticals Q1 Results: Profit Rises by 20.9% YoY - CurrencyVeda
TOP NEWS

Torrent Pharmaceuticals Q1 Results: Profit Rises by 20.9% YoY

USDINR

July 24, 2024

New Delhi, India

Q1 Results

Torrent Pharmaceuticals declared their Q1 results for FY25 on July 23, 2024, showcasing strong financial performance. The company reported a 20.9% year-on-year (YoY) increase in profit and a 10.34% rise in revenue.

Key Financial Highlights:

  • Revenue: The topline increased by 10.34% YoY.
  • Profit: Profit grew by 20.9% YoY.
  • Quarter-on-Quarter (QoQ) Growth: Compared to the previous quarter, revenue grew by 4.15% and profit increased by 1.78%.
  • Expenses: Selling, general & administrative expenses rose by 13.17% QoQ and increased by 10.22% YoY.
  • Operating Income: Operating income was up by 3.97% QoQ and increased by 17.83% YoY.
  • Earnings Per Share (EPS): EPS for Q1 was ₹13.51, an increase of 20.84% YoY.

Union Budget 2024

Market Performance:

  • Return on Investment: Torrent Pharmaceuticals delivered a 6.26% return in the last week, 25.88% return in the last six months, and a 36.14% YTD return.
  • Market Cap: The company currently has a market cap of ₹106,227.9 crore.
  • 52-Week High/Low: The 52-week high/low for the stock is ₹3,176.55 and ₹1,772.05, respectively.

Robust Q1 Performance: Torrent Pharmaceuticals’ Q1 FY25 performance has been robust, driven by strong domestic growth, a solid margin profile, and strategic expansion into the US market. The company’s performance across key parameters in the April-June quarter has been positively received by brokerages.

Market Diversification: While domestic market performance remained strong, sales in Brazil were subdued due to the impact of floods and adverse currency depreciation. Nonetheless, the company is diversifying its markets by strengthening its presence in Germany and the US.

Strategic Moves: Torrent Pharmaceuticals has increased its tender win rate in Germany through cost reduction programs, enhancing its competitiveness. In the US, the company anticipates new product approvals to accelerate, boosting sales growth.

Currency Market Updates

Disclaimer:

CurrencyVeda provides this news article for informational purposes only. We do not offer investment advice or recommendations. Before making any investment decisions, please conduct thorough research, consult with financial experts, and carefully consider your financial situation, risk tolerance, and investment goals. Investing in the stock market carries risks, and it’s essential to make informed choices based on your individual circumstances. CurrencyVeda is not liable for any actions taken based on the information provided in this article.